Loading…

Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age

In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-av...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2007-11, Vol.106 (1), p.127-133
Main Authors: VAN MIEGHEM, T, LEUNEN, K, WILDIERS, H, PARIDAENS, R, SMEETS, A, HENDRICKX, W, VAN LIMBERGEN, E, CHRISTIAENS, M. R, VERGOTE, I, NEVEN, P, POCHET, N, DE MOOR, B, DE SMET, F, AMANT, F, BERTELOOT, P, TIMMERMAN, D, VANDEN BEMPT, I, DRIJKONINGEN, R
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73
cites cdi_FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73
container_end_page 133
container_issue 1
container_start_page 127
container_title Breast cancer research and treatment
container_volume 106
creator VAN MIEGHEM, T
LEUNEN, K
WILDIERS, H
PARIDAENS, R
SMEETS, A
HENDRICKX, W
VAN LIMBERGEN, E
CHRISTIAENS, M. R
VERGOTE, I
NEVEN, P
POCHET, N
DE MOOR, B
DE SMET, F
AMANT, F
BERTELOOT, P
TIMMERMAN, D
VANDEN BEMPT, I
DRIJKONINGEN, R
description In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression. A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression. There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression. In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression.
doi_str_mv 10.1007/s10549-006-9474-7
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68332738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68332738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73</originalsourceid><addsrcrecordid>eNqF0V1rFDEUBuAgit1Wf4A3EoR6Fz1JJl-XttRWKBSK4mXIZE5kyu7MmjMr3X_fGXeh4I1XIeQ5L-S8jL2T8EkCuM8kwTRBAFgRGtcI94KtpHFaOCXdS7YCaZ2wHuwJOyV6AIDgILxmJ3IG0uhmxX5ejN2ebxIR74cOH3kaOn5zdS8UH_9gxcdtRaJ-HOZn3lZMNPGchoyVb9PU4zDRX8gN8D2mOt8KT7_wDXtV0prw7fE8Yz--Xn2_vBG3d9ffLr_ciqy9m4TvFNhcOmuzCd632rRojFfoG7CpzWCKTcFnq6wrLhUwbeg8NKXNrU_J6TP28ZC7rePvHdIUNz1lXK_TgOOOovVaK6f9f6EMFrQNS-KHf-DDuKvD_ImopGqsa9SC5AHlOhJVLHFb-02q-yghLt3EQzdx7iYu3cRl5v0xeNdusHueOJYxg_MjSJTTutR5zz09u6BnabR-Am-plPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212467427</pqid></control><display><type>article</type><title>Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age</title><source>Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List</source><creator>VAN MIEGHEM, T ; LEUNEN, K ; WILDIERS, H ; PARIDAENS, R ; SMEETS, A ; HENDRICKX, W ; VAN LIMBERGEN, E ; CHRISTIAENS, M. R ; VERGOTE, I ; NEVEN, P ; POCHET, N ; DE MOOR, B ; DE SMET, F ; AMANT, F ; BERTELOOT, P ; TIMMERMAN, D ; VANDEN BEMPT, I ; DRIJKONINGEN, R</creator><creatorcontrib>VAN MIEGHEM, T ; LEUNEN, K ; WILDIERS, H ; PARIDAENS, R ; SMEETS, A ; HENDRICKX, W ; VAN LIMBERGEN, E ; CHRISTIAENS, M. R ; VERGOTE, I ; NEVEN, P ; POCHET, N ; DE MOOR, B ; DE SMET, F ; AMANT, F ; BERTELOOT, P ; TIMMERMAN, D ; VANDEN BEMPT, I ; DRIJKONINGEN, R</creatorcontrib><description>In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression. A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression. There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression. In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-006-9474-7</identifier><identifier>PMID: 17211534</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Age Factors ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Body fat ; Body Mass Index ; Breast cancer ; Breast Neoplasms - chemistry ; Breast Neoplasms - genetics ; Breast Neoplasms - physiopathology ; Breast Neoplasms - surgery ; Cancer research ; Cancer therapies ; Estrogens ; Female ; Gene expression ; Gene Expression Regulation, Neoplastic ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Logistic Models ; Mammary gland diseases ; Medical sciences ; Metabolic diseases ; Middle Aged ; Obesity ; Odds Ratio ; Older people ; Oncology ; Postmenopause ; Prospective Studies ; Receptor, ErbB-2 - analysis ; Receptor, ErbB-2 - genetics ; Receptors, Estrogen - analysis ; Receptors, Progesterone - analysis ; Risk Assessment ; Tumors ; Up-Regulation ; Waist-Hip Ratio ; Weight</subject><ispartof>Breast cancer research and treatment, 2007-11, Vol.106 (1), p.127-133</ispartof><rights>2008 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC. 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73</citedby><cites>FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19372153$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17211534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VAN MIEGHEM, T</creatorcontrib><creatorcontrib>LEUNEN, K</creatorcontrib><creatorcontrib>WILDIERS, H</creatorcontrib><creatorcontrib>PARIDAENS, R</creatorcontrib><creatorcontrib>SMEETS, A</creatorcontrib><creatorcontrib>HENDRICKX, W</creatorcontrib><creatorcontrib>VAN LIMBERGEN, E</creatorcontrib><creatorcontrib>CHRISTIAENS, M. R</creatorcontrib><creatorcontrib>VERGOTE, I</creatorcontrib><creatorcontrib>NEVEN, P</creatorcontrib><creatorcontrib>POCHET, N</creatorcontrib><creatorcontrib>DE MOOR, B</creatorcontrib><creatorcontrib>DE SMET, F</creatorcontrib><creatorcontrib>AMANT, F</creatorcontrib><creatorcontrib>BERTELOOT, P</creatorcontrib><creatorcontrib>TIMMERMAN, D</creatorcontrib><creatorcontrib>VANDEN BEMPT, I</creatorcontrib><creatorcontrib>DRIJKONINGEN, R</creatorcontrib><title>Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><description>In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression. A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression. There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression. In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Body fat</subject><subject>Body Mass Index</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - physiopathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Estrogens</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Logistic Models</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Odds Ratio</subject><subject>Older people</subject><subject>Oncology</subject><subject>Postmenopause</subject><subject>Prospective Studies</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptors, Estrogen - analysis</subject><subject>Receptors, Progesterone - analysis</subject><subject>Risk Assessment</subject><subject>Tumors</subject><subject>Up-Regulation</subject><subject>Waist-Hip Ratio</subject><subject>Weight</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqF0V1rFDEUBuAgit1Wf4A3EoR6Fz1JJl-XttRWKBSK4mXIZE5kyu7MmjMr3X_fGXeh4I1XIeQ5L-S8jL2T8EkCuM8kwTRBAFgRGtcI94KtpHFaOCXdS7YCaZ2wHuwJOyV6AIDgILxmJ3IG0uhmxX5ejN2ebxIR74cOH3kaOn5zdS8UH_9gxcdtRaJ-HOZn3lZMNPGchoyVb9PU4zDRX8gN8D2mOt8KT7_wDXtV0prw7fE8Yz--Xn2_vBG3d9ffLr_ciqy9m4TvFNhcOmuzCd632rRojFfoG7CpzWCKTcFnq6wrLhUwbeg8NKXNrU_J6TP28ZC7rePvHdIUNz1lXK_TgOOOovVaK6f9f6EMFrQNS-KHf-DDuKvD_ImopGqsa9SC5AHlOhJVLHFb-02q-yghLt3EQzdx7iYu3cRl5v0xeNdusHueOJYxg_MjSJTTutR5zz09u6BnabR-Am-plPg</recordid><startdate>20071101</startdate><enddate>20071101</enddate><creator>VAN MIEGHEM, T</creator><creator>LEUNEN, K</creator><creator>WILDIERS, H</creator><creator>PARIDAENS, R</creator><creator>SMEETS, A</creator><creator>HENDRICKX, W</creator><creator>VAN LIMBERGEN, E</creator><creator>CHRISTIAENS, M. R</creator><creator>VERGOTE, I</creator><creator>NEVEN, P</creator><creator>POCHET, N</creator><creator>DE MOOR, B</creator><creator>DE SMET, F</creator><creator>AMANT, F</creator><creator>BERTELOOT, P</creator><creator>TIMMERMAN, D</creator><creator>VANDEN BEMPT, I</creator><creator>DRIJKONINGEN, R</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20071101</creationdate><title>Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age</title><author>VAN MIEGHEM, T ; LEUNEN, K ; WILDIERS, H ; PARIDAENS, R ; SMEETS, A ; HENDRICKX, W ; VAN LIMBERGEN, E ; CHRISTIAENS, M. R ; VERGOTE, I ; NEVEN, P ; POCHET, N ; DE MOOR, B ; DE SMET, F ; AMANT, F ; BERTELOOT, P ; TIMMERMAN, D ; VANDEN BEMPT, I ; DRIJKONINGEN, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Body fat</topic><topic>Body Mass Index</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - physiopathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Estrogens</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Logistic Models</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Odds Ratio</topic><topic>Older people</topic><topic>Oncology</topic><topic>Postmenopause</topic><topic>Prospective Studies</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptors, Estrogen - analysis</topic><topic>Receptors, Progesterone - analysis</topic><topic>Risk Assessment</topic><topic>Tumors</topic><topic>Up-Regulation</topic><topic>Waist-Hip Ratio</topic><topic>Weight</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VAN MIEGHEM, T</creatorcontrib><creatorcontrib>LEUNEN, K</creatorcontrib><creatorcontrib>WILDIERS, H</creatorcontrib><creatorcontrib>PARIDAENS, R</creatorcontrib><creatorcontrib>SMEETS, A</creatorcontrib><creatorcontrib>HENDRICKX, W</creatorcontrib><creatorcontrib>VAN LIMBERGEN, E</creatorcontrib><creatorcontrib>CHRISTIAENS, M. R</creatorcontrib><creatorcontrib>VERGOTE, I</creatorcontrib><creatorcontrib>NEVEN, P</creatorcontrib><creatorcontrib>POCHET, N</creatorcontrib><creatorcontrib>DE MOOR, B</creatorcontrib><creatorcontrib>DE SMET, F</creatorcontrib><creatorcontrib>AMANT, F</creatorcontrib><creatorcontrib>BERTELOOT, P</creatorcontrib><creatorcontrib>TIMMERMAN, D</creatorcontrib><creatorcontrib>VANDEN BEMPT, I</creatorcontrib><creatorcontrib>DRIJKONINGEN, R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VAN MIEGHEM, T</au><au>LEUNEN, K</au><au>WILDIERS, H</au><au>PARIDAENS, R</au><au>SMEETS, A</au><au>HENDRICKX, W</au><au>VAN LIMBERGEN, E</au><au>CHRISTIAENS, M. R</au><au>VERGOTE, I</au><au>NEVEN, P</au><au>POCHET, N</au><au>DE MOOR, B</au><au>DE SMET, F</au><au>AMANT, F</au><au>BERTELOOT, P</au><au>TIMMERMAN, D</au><au>VANDEN BEMPT, I</au><au>DRIJKONINGEN, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age</atitle><jtitle>Breast cancer research and treatment</jtitle><addtitle>Breast Cancer Res Treat</addtitle><date>2007-11-01</date><risdate>2007</risdate><volume>106</volume><issue>1</issue><spage>127</spage><epage>133</epage><pages>127-133</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression. A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression. There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression. In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>17211534</pmid><doi>10.1007/s10549-006-9474-7</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-6806
ispartof Breast cancer research and treatment, 2007-11, Vol.106 (1), p.127-133
issn 0167-6806
1573-7217
language eng
recordid cdi_proquest_miscellaneous_68332738
source Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List
subjects Age Factors
Aged
Aged, 80 and over
Biological and medical sciences
Body fat
Body Mass Index
Breast cancer
Breast Neoplasms - chemistry
Breast Neoplasms - genetics
Breast Neoplasms - physiopathology
Breast Neoplasms - surgery
Cancer research
Cancer therapies
Estrogens
Female
Gene expression
Gene Expression Regulation, Neoplastic
Gynecology. Andrology. Obstetrics
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Logistic Models
Mammary gland diseases
Medical sciences
Metabolic diseases
Middle Aged
Obesity
Odds Ratio
Older people
Oncology
Postmenopause
Prospective Studies
Receptor, ErbB-2 - analysis
Receptor, ErbB-2 - genetics
Receptors, Estrogen - analysis
Receptors, Progesterone - analysis
Risk Assessment
Tumors
Up-Regulation
Waist-Hip Ratio
Weight
title Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T09%3A44%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Body%20mass%20index%20and%20HER-2%20overexpression%20in%20breast%20cancer%20patients%20over%2050%20years%20of%20age&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=VAN%20MIEGHEM,%20T&rft.date=2007-11-01&rft.volume=106&rft.issue=1&rft.spage=127&rft.epage=133&rft.pages=127-133&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-006-9474-7&rft_dat=%3Cproquest_cross%3E68332738%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c387t-8d206cfd66c5988b35be5582e8406abc05f6a98c6267f7af05b9d804fbcb8aa73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=212467427&rft_id=info:pmid/17211534&rfr_iscdi=true